Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 22.1197
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 11791797420.0
- FreeCF/Share 1.0821
- PFCF 49.0881
- PE 73.9042
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition
Published: February 19, 2025 by: Investopedia
Sentiment: Positive
Hims & Hers Health (HIMS) shares jumped roughly 20% to a fresh record high on Wednesday following the announcement that the company acquired lab testing facility Trybe Labs.
Read More
Why Hims & Hers Health Stock Is Skyrocketing Today
Published: February 19, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.
Read More
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
Published: February 19, 2025 by: CNBC
Sentiment: Positive
Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
Read More
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. The company has acquired an at-home lab testing facil.
Read More
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently beat its revenue and earnings for the past several quarters, while the management has raised their forward expectations as a result of their Personalized solutions. However, the latest surge in the stock price is attributed to its provocative Super Bowl ad and favorable outlook on the regulatory landscape after RFK Jr.'s appointment as the Health Secretary.
Read More
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
Published: February 18, 2025 by: MarketBeat
Sentiment: Positive
There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, even retiring them from active work if they choose to go that route.
Read More
3 Hot Stocks That Have Already Doubled in 2025
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
We're just a few weeks into 2025, but some stocks are already off to the races. There are already nine U.S. exchange-listed stocks with market caps north of $1 billion that have doubled this year.
Read More
Hims & Hers Stock Is On Fire, But Is It a Bubble?
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
Read More
What Is Driving Hims & Hers Stock Higher?
Published: February 18, 2025 by: The Motley Fool
Sentiment: Neutral
In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Why Hims & Hers Terrifies Big Pharma
Published: February 12, 2025 by: The Motley Fool
Sentiment: Neutral
Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.
Read More
Hims & Hers Health: Explosive Growth Potential Ahead
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $250M in cash, no debt, and strategic share repurchases, enhancing shareholder value. Future growth is expected from personalized solutions, with the potential to expand the subscriber base by millions and grow revenue per subscriber.
Read More
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment.
Read More
Herb Greenberg lays out the risks in Apple, Decker and Hims & Hers
Published: February 10, 2025 by: CNBC Television
Sentiment: Negative
Herb Greenberg, Herb Greenberg on the Street editor, joins 'Power Lunch' to discuss Apple's troubles in China, Deckers headwinds ahead and Hims and Hers core business slump.
Read More
Hims & Hers Super Bowl ad sparks controversy over weight loss drug sourcing
Published: February 10, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Brandon Gomez breaks down the controversy around the Hims & Hers Super Bowl ad.
Read More
Hims & Hers Super Bowl ad draws scrutiny from lawmakers
Published: February 10, 2025 by: Yahoo Finance
Sentiment: Neutral
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Read More
Hims & Hers Health: Meme Potential Could Propel Explosive Growth
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Putting aside Hims meme potential, the company is still in a great position to disrupt the healthcare industry given its unique platform and business model. While Hims is building an increasingly innovative and high-quality business model, the company still faces major regulatory and competitive hurdles.
Read More
Hims & Hers stock price target according to the C&H pattern
Published: February 10, 2025 by: Invezz
Sentiment: Positive
Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has soared by almost 1,500% from its lowest level in 2023, transforming it into a leading juggernaut with a market cap of over $9.3 billion.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637